Pharmacoepigenetics in type 2 diabetes : is it clinically relevant?
Ling, Charlotte LU
(2022)
In Diabetologia
65(11).
p.1849-1853
- Abstract
Data generated over nearly two decades clearly demonstrate the importance of epigenetic modifications and mechanisms in the pathogenesis of type 2 diabetes. However, the role of pharmacoepigenetics in type 2 diabetes is less well established. The field of pharmacoepigenetics covers epigenetic biomarkers that predict response to therapy, therapy-induced epigenetic alterations as well as epigenetic therapies including inhibitors of epigenetic enzymes. Not all individuals with type 2 diabetes respond to glucose-lowering therapies in the same way, and there is therefore a need for clinically useful biomarkers that discriminate responders from non-responders. Blood-based epigenetic biomarkers may be useful for this purpose. There is also a... (More)
Data generated over nearly two decades clearly demonstrate the importance of epigenetic modifications and mechanisms in the pathogenesis of type 2 diabetes. However, the role of pharmacoepigenetics in type 2 diabetes is less well established. The field of pharmacoepigenetics covers epigenetic biomarkers that predict response to therapy, therapy-induced epigenetic alterations as well as epigenetic therapies including inhibitors of epigenetic enzymes. Not all individuals with type 2 diabetes respond to glucose-lowering therapies in the same way, and there is therefore a need for clinically useful biomarkers that discriminate responders from non-responders. Blood-based epigenetic biomarkers may be useful for this purpose. There is also a need for a better understanding of whether existing glucose-lowering therapies exert their function partly through therapy-induced epigenetic alterations. Finally, epigenetic enzymes may be drug targets for type 2 diabetes. Here, I discuss whether pharmacoepigenetics is clinically relevant for type 2 diabetes based on studies addressing this topic.
(Less)
- author
- Ling, Charlotte
LU
- organization
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Adipose tissue, Beta cells, Blood, Blood-based epigenetic biomarkers, DNA methylation, Drug targets, Epigenetic enzymes, Epigenetics, Histone modification, Inhibitors, Liver, Non-coding RNA, Pancreatic islets, Pharmacogenetics, Precision medicine, Skeletal muscle
- in
- Diabetologia
- volume
- 65
- issue
- 11
- pages
- 1849 - 1853
- publisher
- Springer
- external identifiers
-
- pmid:35307762
- scopus:85126555989
- ISSN
- 0012-186X
- DOI
- 10.1007/s00125-022-05681-x
- language
- English
- LU publication?
- yes
- id
- fc2bee09-c7c4-48da-a96b-033016baea1b
- date added to LUP
- 2022-05-02 15:53:35
- date last changed
- 2024-06-13 11:55:20
@misc{fc2bee09-c7c4-48da-a96b-033016baea1b,
abstract = {{<p>Data generated over nearly two decades clearly demonstrate the importance of epigenetic modifications and mechanisms in the pathogenesis of type 2 diabetes. However, the role of pharmacoepigenetics in type 2 diabetes is less well established. The field of pharmacoepigenetics covers epigenetic biomarkers that predict response to therapy, therapy-induced epigenetic alterations as well as epigenetic therapies including inhibitors of epigenetic enzymes. Not all individuals with type 2 diabetes respond to glucose-lowering therapies in the same way, and there is therefore a need for clinically useful biomarkers that discriminate responders from non-responders. Blood-based epigenetic biomarkers may be useful for this purpose. There is also a need for a better understanding of whether existing glucose-lowering therapies exert their function partly through therapy-induced epigenetic alterations. Finally, epigenetic enzymes may be drug targets for type 2 diabetes. Here, I discuss whether pharmacoepigenetics is clinically relevant for type 2 diabetes based on studies addressing this topic.</p>}},
author = {{Ling, Charlotte}},
issn = {{0012-186X}},
keywords = {{Adipose tissue; Beta cells; Blood; Blood-based epigenetic biomarkers; DNA methylation; Drug targets; Epigenetic enzymes; Epigenetics; Histone modification; Inhibitors; Liver; Non-coding RNA; Pancreatic islets; Pharmacogenetics; Precision medicine; Skeletal muscle}},
language = {{eng}},
number = {{11}},
pages = {{1849--1853}},
publisher = {{Springer}},
series = {{Diabetologia}},
title = {{Pharmacoepigenetics in type 2 diabetes : is it clinically relevant?}},
url = {{http://dx.doi.org/10.1007/s00125-022-05681-x}},
doi = {{10.1007/s00125-022-05681-x}},
volume = {{65}},
year = {{2022}},
}